Document:

Restricted Stock Purchase Agreement with Antonio M. Gotto Jr.

 Exhibit 10.12 
 RESTRICTED STOCK PURCHASE AGREEMENT 
 THIS RESTRICTED STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 4th day of April, 2006, by and between
Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and Dr. Antonio M. Gotto, Jr., M.D., D.Phil (the “Equity Participant”). 
 W I T N E S S E T H: 
 WHEREAS, as
consideration for serving as a member of the Board of Directors of Corporation and as Ex-Officio of the Corporation’s Scientific Advisory Board and further for providing other consulting services to the Corporation, the Corporation desires to
issue to the Equity Participant, and the Equity Participant desires to purchase from the Corporation, shares of the Corporation’s Common Stock, $0.001 par value per share (the “Common Stock”). 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties do hereby agree as
follows: 
 SECTION 1. Definitions. 
 As used in this Agreement, the following terms shall have the following respective meanings: 
 “Business Relationship” shall mean service to the Corporation or its successor in the capacity of an independent contractor, consultant or member of the Board of Directors of the Corporation. 
 “Cause” shall mean (i) dishonesty, willful or gross misconduct, or illegal conduct by the Equity Participant in connection with the
Equity Participant’s Business Relationship which in the Corporation’s reasonable judgment may result in damage to the business or reputation of the Corporation, (ii) the Equity Participant’s conviction of, or plea of guilty or
nolo contendere to, a charge of commission of a felony (exclusive of any felony relating to negligent operation of a motor vehicle), and (iii) a material breach by the Equity Participant of this Agreement, the Consulting Agreement or any other
agreement between the Corporation and the Equity Participant; provided, however, in the case of this clause (iii), the Corporation shall be required to give the Equity Participant thirty (30) calendar days prior written notice of its
intention to terminate the Consulting Agreement for Cause and the Equity Participant shall have the opportunity during such thirty (30) day period to cure such event if such event is capable of being cured; provided, further, that in the event
that the Equity Participant terminates his Business Relationship during such thirty (30) day period for any reason, such termination shall be considered a termination for Cause. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 “Commission” shall mean the Securities and Exchange Commission or any other Federal
agency administering the Securities Act at the applicable time. 
 “Consideration” shall have the meaning set forth in
Section 2.1. 
 “Consulting Agreement” shall mean the Consulting Agreement dated as of the date hereof, by and
between the Corporation and the Equity Participant. 
 “Equity Stock” shall have the meaning set forth in Rule 3a11-1 under
the Securities Exchange Act of 1934, as amended, and any successor statute and the rules and regulations thereunder, as shall be in effect from time to time. 
 “Fair Market Value” shall mean the fair market value, with respect to any Share, as determined by the Board of Directors of the Corporation. 
 “Family” shall mean any spouse, lineal ancestor or descendant, or sibling or any trust for the exclusive benefit of any of the foregoing
and/or the Equity Participant. 
 “Group” shall mean as to (a) a partnership, any or all of its general or limited
partners or any “affiliate” thereof (as defined by Rule 405 promulgated under the Securities Act), (b) a trust, any of the beneficiaries, settlers or grantors now existing or hereafter arising of, or any Person under common control
with, such trust, (c) a corporation, any of its stockholders, any subsidiary of such corporation or any corporation which is under common control with such corporation, or any directors, officers or employees of such corporation, and (d) a
limited liability company, any of its members. 
 “Initial Public Offering” shall mean the Corporation’s initial
distribution of New Securities in an underwritten Public Offering to the general public pursuant to a registration statement filed with and declared effective by the Commission pursuant to the Securities Act at a price per New Security of not less
than the product of three (3) and the original purchase price per share for the Corporation’s initial round of Series A Preferred Stock (as adjusted for stock splits, stock dividends or similar recapitalizations) and resulting in net
proceeds to the Corporation of not less than $40 million. 
 “IRS” shall mean the Internal Revenue Service. 
 “New Securities” shall mean any Equity Stock, including, but not limited to, shares of Common Stock, any security which is convertible
into or exercisable or exchangeable for Common Stock, or any right, option or warrant to acquire any Common Stock. 
 “Original Cost
Per Share” shall have the meaning set forth in Section 2.1. 
 “Person” shall mean and include a
natural person, a corporation, a partnership, a limited liability company, a trust, an unincorporated organization, an educational institution, a government or any department, agency or political subdivision thereof, or any other entity. 

“Preferred Shares” shall mean, at the applicable time, all issued and outstanding shares, if any, of the Corporation’s preferred
stock. 
  

 2 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 “Public Offering” shall mean a distribution of New Securities in a firm commitment
underwritten public offering to the general public pursuant to a registration statement filed with and declared effective by the Commission pursuant to the Securities Act. 
 “Released Shares” shall mean Shares that are not Unreleased Shares. 
 “Securities Act” shall mean the Securities Act of 1933, as amended, and any successor statute and the rules and regulations of the
Commission thereunder, as shall be in effect at the applicable time. 
 “Shares” shall have the meaning set forth in
Section 2.1. 
 “Transfer” shall include any direct or indirect sale, assignment, transfer, pledge (but not
including a pledge in favor of the Corporation), hypothecation or other disposition of any Shares or of any legal or beneficial interest therein. 
 “Unreleased Shares” means Shares that, in accordance with Sections 3.1, 3.3, and 3.3, have not been released and are subject to repurchase by the Corporation at the Original Cost Per Share
pursuant to Section 4.1. 
 SECTION 2. Issuance of Common Stock. 
 2.1 Subject to the terms and conditions contained herein, the Corporation hereby sells to the Equity Participant, and the Equity Participant hereby
purchases from the Corporation, 50,000 shares of Common Stock (the “Shares”) for a purchase price of $.001 per share (the “Original Cost Per Share”) or the aggregate purchase price of $50.00 (the
“Consideration”). Simultaneously with execution and delivery hereof, the Equity Participant is delivering to the Corporation a check or wire transfer of funds in the aggregate amount of the Consideration. 
 2.2 The Equity Participant, in his sole discretion, may make an effective election with the IRS under Section 83(b) of the Code and the regulations
promulgated thereunder in the form of Exhibit A attached hereto. The Equity Participant understands that under applicable law such election must be filed with the IRS no later than thirty (30) days after any acquisition of the Shares to
be effective. If the Equity Participant files an effective election, the excess of the fair value of the Shares (which the IRS may assert is different from the fair value determined by the Equity Participant) covered by such election over the amount
paid by the Equity Participant for the Shares shall be treated as ordinary income received by the Equity Participant. If the Equity Participant does not file an effective election, future appreciation on the Shares will generally be taxable as
ordinary income when the right of repurchase lapses as to such Shares pursuant to this Agreement. The foregoing is merely a brief summary of complex tax regulations, and therefore, the Equity Participant is strongly advised to consult with his own
tax advisors. 
 2.3 In the event that the Equity Participant files the election referred to in Section 2.2, the Equity
Participant will provide the Corporation with a copy of such election as filed. 
 2.4 The Corporation will reimburse the Equity Participant
in an amount not to exceed $10,000 for Equity Participant’s federal income, state income (net of any federal deduction) and self employment tax (net of any federal or, if applicable, state income tax deduction) incurred on 

  

 3 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 
account of the income the Equity Participant recognizes in 2006 for tax purposes with respect to the issuance of the Shares and the election referred to in
Section 2.2 (if made), calculated using the Equity Participant’s applicable statutory marginal tax rates on such income after taking into account all other income in 2006 set forth on Equity Participant’s 2006 tax return, and
determined without regard to phase-outs of tax credits and deductions or other adjustments that may impact the Equity Participant’s true effective marginal tax rate. 
 SECTION 3. Repurchase Rights related to Common Stock. 
 3.1 The Shares shall be released in accordance
with the following and as detailed on Schedule A attached hereto: (a) twenty-five percent (25%) of the Shares on the date hereof; and (b) the balance of the Shares in a series of eight (8) successive quarterly installments
over the twenty-four (24) month period measured from the first anniversary of the date hereof. In no event shall any additional Shares be released after the Equity Participant’s cessation of service, except as expressly provided in
Sections 3.2 and 3.3. 
 3.2 In the event the Equity Participant’s Business Relationship is terminated by the
Corporation without Cause in relation to the sale or other disposition of all or substantially all of the Corporation’s assets or a change in ownership in a single transaction or series of related transactions of fifty percent (50%) or
more of the Corporation’s stock, the Shares which remain unreleased at the time of termination, after the release of those Shares pursuant to Section 3.1, shall be released on the date of such termination and become Released Shares;
provided, however that this provision shall not apply in the event of any equity financings of the Corporation. 
 3.3 In the event the
Equity Participant’s Business Relationship is terminated by the Corporation without Cause, twenty-five percent (25%) of the Unreleased Shares on the date of such termination shall be released on the date of such termination and become
Released Shares. 
 SECTION 4. Termination of Relationship. 
 4.1 In the event that the Equity Participant’s Business Relationship ceases for any reason (with or without Cause), the Corporation shall have the
right to purchase from the Equity Participant, and if the Corporation exercises its option pursuant to this Section 4, the Equity Participant shall sell to the Corporation upon the exercise of such right, (1) all of the Equity
Participant’s Unreleased Shares (rounded up to the nearest whole Share) at the Original Cost Per Share, and (2) all of the Equity Participant’s Released Shares (rounded up to the nearest whole Share) at the Fair Market Value per
Share; provided, however, that if the Equity Participant’s Business Relationship is terminated by the Corporation for Cause, the purchase price for any Released Shares shall be the Original Cost Per Share. 
 4.2 The number of Shares subject to purchase pursuant to Section 4.1 shall be adjusted to give effect to any stock dividend, or other
distribution of stock made on or in respect of such Shares, or any subdivision, combination or reclassification of the outstanding capital stock of the Corporation or received in exchange for the Shares. 
  

 4 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 4.3 In order to exercise the option to purchase the Equity Participant’s Shares under this
Section 4, the Corporation shall deliver a written notice to the Equity Participant (the “Share Repurchase Notice”), indicating its election to purchase any or all of the Shares and specifying the number of Unreleased
Shares and Released Shares, if applicable, which the Corporation elects to purchase and the purchase price therefor, within ninety (90) days after the Equity Participant’s termination. 
 4.4 The repurchase of Shares hereunder shall be made on a date within sixty (60) days of the delivery of the Share Repurchase Notice, by delivery of
payment to the Equity Participant, by check or wire transfer, against receipt of one or more certificates, properly endorsed, evidencing the Equity Participant’s Unreleased and/or Released Shares, if applicable, to be so purchased. If the
repurchase is not consummated by such date, the Corporation may deliver to the Equity Participant by check or wire transfer the applicable repurchase price for the Unreleased Shares and/or Released Shares, if applicable, to be repurchased and may
cancel the certificates evidencing such Unreleased Shares and/or Released Shares, if applicable, on the books and records of the Corporation. 
 4.5 Notwithstanding anything to the contrary contained in this Agreement, all repurchases of Shares by the Corporation shall be subject to applicable restrictions contained in federal law, the Delaware General Corporation Law and in the
Corporation’s debt and equity financing agreements. Notwithstanding anything to the contrary contained in this Agreement, if any such restrictions prohibit or otherwise delay the repurchase of any Shares thereunder which the Corporation is
otherwise entitled to make, the Corporation may make such repurchases within sixty (60) days of the date that it is permitted to do so under such restrictions. 
 4.6 In the event that any Shares are the subject of repurchase by the Corporation pursuant to this Section 4, the Equity Participant and his successors, assigns or representatives will take all steps
necessary and desirable to obtain all required third-party, governmental and regulatory consents and approvals and take all other actions necessary and desirable to facilitate consummation of such repurchase(s) in a timely manner as are requested by
the Corporation. 
 SECTION 5. Legend on Shares and Notice of Transfer. 
 5.1 Restrictive Legends. (a) Each certificate evidencing Shares, and each certificate evidencing Shares held by subsequent transferees of any
such certificate, shall (unless otherwise permitted by the provisions of Section 5.2) be stamped or otherwise imprinted with a legend in substantially the following form: 
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR ANY EXEMPTION THEREFROM UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW. 
  

 5 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 (b) Each certificate evidencing Shares, and each certificate evidencing Shares held by subsequent
transferees of any such certificate, shall also be stamped or otherwise imprinted with a legend in substantially the following form: 
 ADDITIONALLY, THE TRANSFER OF THESE SECURITIES IS SUBJECT TO THE TERMS AND CONDITIONS OF A RESTRICTED STOCK PURCHASE AGREEMENT EFFECTIVE AS OF APRIL 4, 2006, BETWEEN AEGERION PHARMACEUTICALS, INC. AND THE HOLDER OF RECORD OF THIS
CERTIFICATE AND NO SALE, ASSIGNMENT, TRANSFER, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF SUCH SECURITIES SHALL BE VALID OR EFFECTIVE EXCEPT IN ACCORDANCE WITH SUCH AGREEMENT AND UNTIL SUCH TERMS AND CONDITIONS HAVE BEEN FULFILLED. COPIES OF SUCH
AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF AEGERION PHARMACEUTICALS, INC. 
 5.2 Notice of Transfer. (a) The Equity Participant, and any other holder of any Shares by acceptance thereof, agrees that, prior to any Transfer of any Shares, such holder will give written notice to the
Corporation of such holder’s intention to effect such Transfer and to comply in all other respects with the provisions of this Section 5.2. Each such notice shall contain (i) a statement setting forth the intention of said
holder’s prospective transferee with respect to its retention or disposition of said Shares; and (ii) unless waived by the Corporation, an opinion of counsel for said holder as to the necessity or non-necessity for registration under the
Securities Act and applicable state securities laws in connection with such Transfer and stating the factual and statutory basis relied upon by counsel. The following provisions shall then apply: 
 (i) If the proposed Transfer of Shares may be effected without registration or qualification under the Securities Act and any applicable state securities
laws, then the registered holder of such Shares shall be entitled to Transfer such Shares in accordance with this Section 5 and the intended method of disposition specified in the statement delivered by said holder to the Corporation.

 (ii) If the proposed Transfer of such Shares may not be effected without registration under the Securities Act or registration or
qualification under any applicable state securities laws, the registered holder of such Shares shall not be entitled to Transfer such Shares pursuant to Section 6 until the requisite registration or qualification is effective.

 (b) Notwithstanding the provisions of Section 5.2(a), in the case of a Transfer by a holder to a member of such holder’s
Family or Group, no such opinion of counsel shall be necessary; provided, that the transferee agrees in writing to be subject to this Section 5 to the same extent as if such transferee were originally a signatory to this Agreement.

  

 6 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 (c) Each certificate evidencing the Shares issued upon such Transfer (and each certificate evidencing
any untransferred balance of such Shares) shall bear the legend set forth in Section 5.1(a) hereof unless (i) in the opinion of counsel (acceptable to the Corporation) addressed to the Corporation the registration of future
Transfers is not required by the applicable provisions of the Securities Act or applicable state securities laws; (ii) the Corporation shall have waived the requirement of such legend; or (iii) in the reasonable opinion of counsel to the
Corporation, such Transfer shall have been made in connection with an effective registration statement filed pursuant to the Securities Act or in compliance with the requirements of Rule 144 or Rule 144A (or any similar or successor rule)
promulgated under the Securities Act, and in compliance with applicable state securities laws. 
 (d) Each certificate evidencing the Shares
issued upon such Transfer (and each certificate evidencing any untransferred balance of such Shares) shall bear the legend set forth in Section 5.1(b) for so long as this Agreement remains in effect. In the event of the termination of
this Agreement, the holder of Shares may request that the Corporation issue a new certificate not bearing the legend set forth in Section 5.1(b). 
 SECTION 6. Covenants of the Equity Participant and the Corporation. 
 6.1 Permitted Transfers.

 (a) Neither the Equity Participant nor any permitted transferee of the Equity Participant shall Transfer all or any of the Shares to
any Person except in accordance with Sections 3 and 4. Notwithstanding anything to the contrary contained herein (other than Section 3), the Equity Participant (and any permitted transferee of the Equity Participant) may
Transfer all or any portion of his Shares: (i) if the stockholder is a limited partnership or a trust, to any member of the Group of which the Equity Participant (or such permitted transferee) is a member; provided, that such transferee shall
agree in writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement; (ii) if the stockholder is a corporation or a limited liability company, to any member of its
Group; provided, that such transferee shall agree in writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement; (iii) if the stockholder is an individual, to any
member of the Family of such stockholder; provided, that such new transferee shall agree in writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement and, provided,
further, that the interests in any Family trusts shall be non-transferable; and (iv) if the transferor is a permitted transferee of the Equity Participant by will or the laws of descent and distribution, provided that each such new transferee
shall be bound by all of the provisions of this Agreement to the same extent as if such transferee was a party hereto. 
 (b) If requested in
writing by the managing underwriters, if any, of any Initial Public Offering, the Equity Participant agrees not to offer, sell, contract to sell or otherwise dispose of any Shares except as part of such Initial Public Offering within thirty
(30) days before or one hundred and eighty (180) days after the effective date of the registration statement filed with respect to said offering; provided, however, that this restriction will not apply to transfers permitted under
Section 6.1(a) provided such transferee agrees to be bound by the restriction contained in this Section 6.1(b). 
  

 7 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 6.2 Right of First Offer on Dispositions. 
 (a) If Equity Participant desires to Transfer all or any part of his Shares pursuant to this Section 6.2 at any time prior to completion of
the Corporation’s Initial Public Offering (other than pursuant to Section 6.1(a) or 6.3), Equity Participant shall submit a written offer (the “Offer”) to sell such Shares (the “Offered
Shares”) to the Corporation, which Offer shall specify the number of Offered Shares proposed to be sold, the total number of Shares owned by Equity Participant, and the terms and conditions, including price, at which the Shares are being
offered. 
 (b) The Corporation shall have the right to purchase any or all of the Offered Shares on the same terms and conditions specified
in the Offer. 
 (c) If the Corporation desires to purchase any or all of the Offered Shares on the same terms and conditions specified in
the Offer, the Corporation shall deliver its acceptance (an “Acceptance”) to Equity Participant, which Acceptance shall confirm that the Corporation desires to purchase any or all of the Offered Shares and the number of Shares the
Corporation desires to purchase and shall be delivered in person or mailed to Equity Participant at the address set forth in the Offer within twenty (20) days of the date the Offer was made by Equity Participant pursuant to
Section 6.2(a). 
 (d) If the Corporation elects to purchase any or all of the Offered Shares, sale of the Offered Shares
pursuant to this Section 6.2 shall be made at the offices of the Corporation on the 30th day following the expiration of the 20-day period described above (or if such 30th day is not a business day, then on the next succeeding business
day). Such sale shall be effected by Equity Participant’s delivery to the Corporation of a certificate or certificates evidencing the Offered Shares to be purchased by it, duly endorsed for transfer to the Corporation, which Offered Shares
shall be delivered free and clear of all liens, charges, claims and encumbrances of any nature whatsoever, against payment to Equity Participant of the purchase price therefor by the Corporation. Payment for the Offered Shares shall be made as
provided in the Offer or by wire transfer or certified check. 
 (e) If the Corporation does not elect to purchase all of the Offered Shares,
then the Offered Shares (less the amount to be purchased by the Corporation) may be sold by Equity Participant at any time within one hundred twenty (120) days after the date the Corporation responded to the Offer was made by Equity Participant
pursuant to Section 6.2(a). Any such sale shall be upon terms and conditions, including price, no more favorable to the proposed transferee than those specified in the Offer. Any Offered Shares not sold within such 120-day period shall
continue to be subject to the requirements of a prior offer pursuant to this Section 6.2. 
 6.3 Drag Along. Subject to
Section 6.2, anything in this Agreement to the contrary notwithstanding, in the event that (i) the Board of Directors of the Corporation by unanimous vote or unanimous written consent and/or the holders of more than fifty percent
(50%) of the then outstanding Common Stock by vote or written consent approves a transaction pursuant to which any Person or Persons not affiliated with any of the holders of any Common Stock will acquire fifty percent (50%) or more of the
Common Stock of the Corporation (by stock purchase, 

  

 8 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 
merger or otherwise) or all or substantially all of the assets of the Corporation, upon the written request of the holders of more than fifty percent
(50%) of the Common Stock, the Equity Participant agrees to offer to sell all of his Shares, and to sell all of his Shares (or, if such proposed transaction involves the sale of less than one hundred percent (100%) of the outstanding
Common Stock, a proportionate amount of his Shares), to such Person or Persons or to vote all of his Shares in favor of the sale of assets, as the case may be, in either case upon the terms and conditions of the transaction approved by the Board of
Directors of the Corporation and/or the holders of more than fifty percent (50%) of the Common Stock; provided, however, that the Equity Participant’s obligation to sell his Shares pursuant to this Section 6.3 shall only apply
if all of the Shares are to be sold on the same terms and conditions as the shares of such other Person or Persons. For purposes of this Section 6.3, each Preferred Share shall be deemed to be the number of shares of Common Stock into
which such Preferred Share is then convertible. 
 6.4 “Piggyback” Registrations. (a) If the Corporation at any time
proposes to register any of its securities under the Securities Act on Form S-1, S-2 or S-3 or on any other form upon which the Common Stock may be registered for sale to the general public, other than on Form S-4 or S-8 or other similar
registration statement not generally used by an issuer in connection with raising capital, whether for its own account or for the account of others, the Corporation will at each such time promptly give written notice to the Equity Participant of
such proposal, which shall set forth information, to the extent then known, as to offering price or range, the number of shares to be offered, the proposed manner of distribution and the proposed managing underwriter(s) of the offering. Upon the
written request of the Equity Participant given within twenty (20) days after the Corporation has given such notice and subject to any rights of the holders of Preferred Shares of the Corporation, the Corporation will cause the Shares which the
Corporation has been requested to register by the Equity Participant to be registered under the Securities Act (and any related qualification under blue sky laws or other compliance), all to the extent required to permit the sale or other
disposition by the Equity Participant of the Shares so registered. 
 (b) If securities are to be registered for sale under a registration
and are to be distributed for the account of the Corporation by or through a firm of underwriter(s), then, subject to the rights of the holders of Preferred Shares of the Corporation, any Shares which the Corporation has been requested to register
pursuant to clause (a) of this Section 6.4 shall also be included in such underwriting on the same terms as other securities of the same class as the Shares included in such underwriting; provided, that if, in the written opinion of
the managing underwriter(s), the total amount of such securities to be so registered, when added to the Shares, will exceed the maximum amount of the Corporation’s securities which can be marketed (i) at a price reasonably related to their
then current market value, or (ii) without otherwise materially and adversely affecting the entire offering, then (subject to clause (d) of this Section 6.4) the Corporation shall exclude from such underwriting, first, the
number of Shares being sold for the account of the Equity Participant as is necessary, in the opinion of the managing underwriter(s), to reduce the size of the offering provided, however, that the number of securities to be requested
to be sold in the offering by officers, directors and other founding stockholders are likewise reduced pro rata based upon the number of securities requested to be registered. 
  

 9 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 (c) If securities are to be registered for sale under a registration and are to be distributed for
the account of holders of Common Stock held by third parties or holders (other than the Corporation) of other securities of the Corporation other than Common Stock by or through a firm of underwriter(s) of recognized standing under underwriting
terms appropriate for such transaction, then any Shares which the Corporation has been requested to register pursuant to clause (a) of this Section 6.4 shall also be included in such underwriting on the same terms as other
securities included in such underwriting, provided, that if, in the written opinion of the managing underwriter(s), the total amount of such securities to be so registered, when added to such Shares, will exceed the maximum amount of the
Corporation’s securities which can be marketed (i) at a price reasonably related to their then current market value, or (ii) without otherwise materially and adversely affecting the entire offering, then the Corporation shall exclude
from such underwriting the number of Shares and other securities, pro rata to the extent practicable, on the basis of the number of securities requested to be registered, as is necessary in the opinion of the managing underwriter(s) to reduce the
size of the offering; provided, however, that the number of securities to be requested to be sold in the offering by officers, directors and other founding stockholders are likewise reduced pro rata based upon the number of securities
requested to be registered. 
 (d) Notwithstanding Sections 6.4(a), (b) and (c), the Corporation may exclude
all Shares from registration in connection with the Corporation’s Initial Public Offering if the inclusion of such Shares would, in the written opinion of the managing underwriter(s) adversely affect the marketing of the New Securities to be
sold by the Corporation therein; provided that such exclusion of Shares shall be made pro rata with all other shares of Common Stock held by third parties issued prior to the issuance and sale of the Preferred Shares; provided, further, that such
shares of Common Stock shall not include shares of Common Stock received by third parties pursuant to conversion of Preferred Shares. 
 SECTION 7. Representations. 
 7.1 Representations of the Equity Participant. In connection with the Equity
Participant’s purchase of any Shares on the date hereof, the Equity Participant hereby represents and warrants to the Corporation as follows: 
 (a) Investment Intent; Capacity to Protect Interests. The Equity Participant is acquiring the Shares solely for his own account for investment and not with a view to or for sale in connection with any distribution of the Shares or
any portion thereof and not with any present intention of selling, offering to sell or otherwise disposing of or distributing the Shares or any portion thereof in any transaction other than a transaction exempt from registration under the Securities
Act. 
 (b) Restricted Securities. The Equity Participant understands and acknowledges that the sale of the Shares has not been
registered under the Securities Act; that the Shares must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; and that, except as provided in Section 6.3, the
Corporation is under no obligation to register the Shares. The Equity Participant has no need for liquidity relating to his investment in the Shares and is able to bear the economic risk of his investment in the Shares for an indefinite period of
time. 
  

 10 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 (c) Disposition under Rule 144. The Equity Participant understands that the Shares are
restricted securities within the meaning of Rule 144 promulgated under the Securities Act; that the exemption from registration under Rule 144 will not be available in any event for at least one (1) year from the date of purchase of any payment
for the Shares, and even then will not be available unless (i) a public trading market then exists for the Shares, (ii) adequate information concerning the Corporation is then available to the public, and (iii) other terms and
conditions of Rule 144 are complied with; and that any sale of the Shares may be made only in limited amounts in accordance with such terms and conditions. 
 (d) Knowledge. The Equity Participant has generally such knowledge and experience in business and financial matters and with respect to investments in securities of privately held companies so as to enable him
to understand and evaluate the risks and benefits of his investment in the Shares. The Equity Participant has had an opportunity to ask questions and receive answers concerning the terms and conditions of the offering of the Shares and has had full
access to or been provided with such other information concerning the Corporation as he has requested. 
 7.2 Representations of the
Corporation. The Corporation represents to the Equity Participant that: 
 (a) The execution, delivery and performance by the Corporation
of this Agreement and all transactions contemplated by this Agreement have been duly authorized by all action required by law, its Certificate of Incorporation, its Bylaws or otherwise. 
 (b) This Agreement has been duly executed and delivered by the Corporation and constitutes the legal, valid and binding obligation of the Corporation
enforceable against it in accordance with its terms. 
 SECTION 8. Withholding. Upon the request of the Corporation, the Equity
Participant shall promptly pay to the Corporation, or make arrangements satisfactory to the Corporation regarding payment of, any Federal, state or local taxes of any kind required by law to be withheld with respect to the Shares (or any
distributions of other securities or property (including cash) thereon or issued in replacement thereof). 
 SECTION 9. Remedies. In
case any one or more of the covenants and/or agreements set forth in this Agreement shall have been breached by any party hereto, the party entitled to the benefit of such covenants or agreements may proceed to protect and enforce its rights either
by suit in equity and/or by action at law, including, but not limited to, (a) an action for damages as a result of any such breach, (b) an action for specific performance of any such covenant or agreement contained in this Agreement, and/or (c) a
temporary or permanent injunction, in any case without showing any actual damage. The rights, power and remedies of the parties under this Agreement are cumulative and not exclusive of any other agreement or law. No single or partial assertion or
exercise of any right, power or remedy of a party hereunder shall preclude any other or further assertion or exercise thereof. Any purported Transfer in violation of the provisions of this Agreement shall be null and void ab initio. 
  

 11 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 SECTION 10. Successors and Assigns. Except as otherwise expressly provided herein, this
Agreement shall bind and inure to the benefit of the Corporation, the Equity Participant, the respective successors or heirs, distributees and personal representatives and permitted assigns of the Corporation and the Equity Participant, and each
other person who shall properly become a registered holder of any Shares that have not theretofore been sold to the public pursuant to a registration statement under the Securities Act or Rule 144 or Rule 144A (or any similar or successor rule).

 SECTION 11. Entire Agreement. This Agreement, together with the Consulting Agreement, contains the entire agreement among the
parties with respect to the subject matter hereof and supersedes other prior and contemporaneous arrangements or understandings with respect thereto. 
 SECTION 12. Notices. All notices, consents and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered by hand, (b) one (1) business day
after the business day of transmission, if sent by telex or telecopier (with receipt confirmed), provided that a copy is mailed by registered mail, return receipt requested, or (c) one (1) business day after the business day of deposit with the
carrier, if sent by Express Mail, Federal Express or other nationally-recognized express delivery service (receipt requested), in each case to the appropriate addresses, telex numbers and telecopier numbers set forth below (or to such other
addresses or telecopy numbers as a party may designate as to itself or herself by notice to the other party): 
  

	 	(a)	If to the Equity Participant: 

 Dr. Anthony M.
Gotto, Jr., M.D., D.Phil 
 c/o Aegerion Pharmaceuticals, Inc. 
 250 West Main Street 
 Branford, Connecticut 06405 
  

	 	(b)	If to the Corporation: 

 Aegerion Pharmaceuticals, Inc.

 c/o Scheer & Company, Inc. 
 250 West Main Street 
 Branford, Connecticut 06405 
 Telecopier: (203) 481-4164 
 Attention: David I. Scheer, Chairman 
 with a copy to: 
 Goodwin Procter LLP

 Exchange Place 
 Boston,
Massachusetts 02109 
 Telecopier: (617) 570-1231 
 Attention: Kingsley L. Taft, Esq. 
  

 12 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 SECTION 13. Changes. The terms and provisions of this Agreement may not be modified or
amended, or any of the provisions hereof waived, temporarily or permanently, without the prior written consent of each of the parties hereto. 
 SECTION 14. Counterparts. This Agreement may be executed in any number of counterparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement and
that execution may be delivered by facsimile. 
 SECTION 15. Headings. The benefits of the various sections of this Agreement have
been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. 
 SECTION 16. Nouns and
Pronouns. Whenever the context may require, any pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 
 SECTION 17. Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability. Such prohibition or unenforceability in any one jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 SECTION 18. Governing Law; Jurisdiction. This Agreement and (unless otherwise provided) all amendments hereof and waivers and consents hereunder
shall be governed by the internal law of the State of New Jersey, without regard to the conflicts of law principles thereof. Each party hereby submits itself or himself, for the sole purpose of this Agreement and any controversy arising hereunder,
to the exclusive jurisdiction of the state and Federal courts located in the State of New Jersey, and waives any objection (on the grounds of lack of jurisdiction, forum non conveniens or otherwise) to the exercise of such jurisdiction over it or
him by any such court in the State of New Jersey. Each party hereby agrees that service of process may be served on it or him by certified mail, return receipt requested, or overnight courier, sent to the address of such person or entity or such
person’s or entity’s attorneys listed in Section 12 above (or such other address as any such party notifies the other thereof by written notice). 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 13 

 RESTRICTED STOCK PURCHASE AGREEMENT

  

 IN WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Purchase Agreement as of
the date and year first written above. 
  

			
	 AEGERION PHARMACEUTICALS, INC.

		
	By:	 	 /s/ David Scheer

	Name:	 	David Scheer
	Title:	 	Chairman
	
	 /s/ Antonio M. Gotto, Jr.

	 Dr. Anthony M. Gotto, Jr., M.D., D.Phil

 Schedule A 
 Vesting Schedule 
  

			
	 Date of Release
	  	 Number of Shares Released

	 4 April 2006
  
	  	12,500 Shares
	1 April 2007	  	4,688 Shares
	1 July 2007	  	4,688 Shares
	1 October 2007	  	4,688 Shares
	1 January 2008	  	4,688 Shares
	1 April 2008	  	4,687 Shares
	1 July 2008	  	4,687 Shares
	1 October 2008	  	4,687 Shares
	1 January 2009	  	4,687 Shares
	TOTAL:	  	50,000 Shares

 Exhibit A 
 Form of 83(b) Election 
 ELECTION PURSUANT TO SECTION 83(b) OF THE 
 INTERNAL REVENUE CODE 
 The undersigned hereby
makes the election authorized by Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations thereunder, with respect to shares of Common Stock of Aegerion Pharmaceuticals, Inc.
(the “Company”) described below acquired by the undersigned on the date shown below. To the extent permitted, this election shall also serve as an election under analogous state law. As required by the Treasury Regulations
under Section 83(b), the undersigned supplies herewith the following information: 
 1. The undersigned’s name and address are: 
 Name: 
 Address: 
 2. The undersigned has taxpayer identification number
                    ; 
 3. The property with
respect to which this protective election is made consists of                      shares of Common Stock of the Company. 
 4. The date on which the above-described property was transferred to the undersigned was
                    . 
  

	5.	As of the date of transfer, the property was subject to the following substantial risk of forfeiture: 

 (a) All of the shares are subject to time vesting based on a continued business relationship with the Company. 
 (b) All of the shares which have not been “released” are subject to repurchase by the Company in the event the
undersigned’s business relationship with the Company ceases for any reason. The purchase price for each share of Common Stock which has not yet been “released” and is subject to repurchase will be the undersigned’s original cost
per share. 
 (c) All of the shares which have been “released” are subject to repurchase by the Company in the event
the undersigned’s business relationship with the Company is terminated for Cause. The purchase price for each share of Common Stock which has been “released” and is subject to repurchase will be the undersigned’s original cost
per share. 
 (d) All of the shares which have been “released” are subject to repurchase by the Company in the event
the undersigned’s business relationship with the Company 

 
ceases for any reason other than Cause. The purchase price for each share of Common Stock which has been “released” and is subject to repurchase
will be the fair market value of such share. 
 6. The fair market value of the property at the time of transfer (determined without regard to any
restrictions other than restrictions which by their terms will never lapse) was $             per share. 
 7. The amount paid for the property by the undersigned was $0.001 per share (“Original Cost Per Share”). 
 A copy of this election has been furnished to the Company, and a copy of this election will be attached to the undersigned’s federal income tax return for the year to which this election relates. 
  

			
	  

	 Name:
	 	
		
	Date:	 	  

 Amendment No. 1 to Restricted Stock Purchase Agreement 
 This Amendment No. 1 to Restricted Stock Purchase Agreement (the “Amendment”) is made as of this 13 day of June 2007, by and
between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) and Antonio M. Gotto, Jr. M.D., D.Phil (the “Equity Participant”), parties to that certain Restricted Stock Purchase Agreement dated
as of April 4, 2006 (the “Agreement”). Capitalized terms used herein, unless otherwise defined herein, shall have the meanings ascribed to them in the Agreement. 
 WHEREAS, the Corporation and the Equity Participant desire to amend the Agreement; and 
 WHEREAS, pursuant to Section 13 of the Agreement, a waiver, amendment or modification to the terms and provisions of the Agreement may not be
effected without the prior written consent of the Corporation and the Equity Participant. 
 NOW, THEREFORE in consideration of the
foregoing and intending to be legally bound, the Company and the Equity Participant agree as follows. 
 1. The definition of “Initial Public
Offering” contained in Section 1 of the Agreement is amended and restated in its entirety to read as follows: 
 “Initial
Public Offering” shall mean the Corporation’s initial distribution of New Securities in a firm commitment underwritten public offering to the general public pursuant to a registration statement filed with and declared effective by the
Commission pursuant to the Securities Act. 
 2. Section 6.3 of the Agreement shall terminate upon an Initial Public Offering. 
 3. This Amendment shall be deemed to be a contract made under, and shall be construed in accordance with, the laws of the State of Delaware, without giving effect to
conflict of interest laws principles thereof. 
 4. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. 
 5. Except to the extent amended hereby, the terms and provisions of the Agreement
shall remain in full force and effect. 
 [SIGNATURE PAGE FOLLOWS] 
  

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Restricted Stock
Purchase Agreement as of the date and year first written above. 
 AEGERION PHARMACEUTICALS, INC. 
 By /s/ Gerald Wisler 
 Name: Gerald Wisler 
 Title: President and Chief Executive Officer 
 /s/ Antonio M. Gotto, Jr. M.D., D.Phil 
 Antonio M. Gotto, Jr. M.D., D.PhilConsulting Agreement with Antonio M. Gotto Jr.

 Exhibit 10.13 
 CONSULTING AGREEMENT 
 THIS CONSULTING AGREEMENT (this “Agreement”) is dated as of
the 4th day of, April, 2006, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Antonio M. Gotto, Jr., M.D., D.Phil (“Consultant”). 
 In consideration of the mutual promises and agreements set forth herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: 
 1. Consulting Services. The Company
hereby engages Consultant to perform the services (the “Services”), including, but not limited to, serving as a member of the Board of Directors (the “Board”) and Ex-Officio member of the Company’s Scientific
Advisory Board (“SAB”). The parties agree that Consultant shall devote on average 12 days per year (commencing on the date hereof) attending Board Meetings, on average two (2) days per year attending SAB meetings, and on
average four (4) half days per year for non-specific consulting activities on behalf of the Company; provided that Consultant shall devote approximately 48 days in the aggregate over a three (3) year period. To the extent the Company
requires that Consultant devote any additional days, the parties shall mutually agree on the actual number of additional days that Consultant shall devote, as well as the appropriate rate of compensation. Consultant shall perform the Services at the
Company’s principal offices or such other location as may be mutually agreed upon by the parties and shall use his best efforts to attend Board and SAB meetings when requested by the Company. 
 2. Term. The term of this Agreement (the “Term”) shall be for an initial period of three (3) years from the date hereof;
provided, however, that (a) this Agreement may be terminated by either party upon at least sixty (60) days’ prior written notice to the other party, and (b) if either party breaches in any material respect any of its material
obligations under this Agreement, in addition to any other right or remedy, the non-breaching party may terminate this Agreement in the event that the breach is not cured within thirty (30) days after receipt by such party of written notice of
such breach. Notwithstanding any expiration or termination of this Agreement, Consultant and the Company may mutually agree to have Consultant continue serving on the Board. 
 3. Compensation and Expenses. For performance of the Services, the Company shall pay Consultant an annual rate of $20,000, payable in four equal
installments within thirty (30) days of the start of each calendar quarter. Consultant shall also receive compensation for attendance of meetings of the Board of Directors at the rate of $1,000 per in-person meeting and $500 per telephonic
meeting. For attendance as an Ex-officio member of the SAB, the Company shall pay Consultant a rate of $3,000 per in-person meeting and a rate of $1,000 per telephonic meeting. Compensation for both Board of Directors and SAB meetings shall be paid
upon submission of invoices. In addition, the Consultant shall have the right to purchase 50,000 shares of Common Stock, $0.001 par value per share, of the Company, pursuant to a Restricted Stock Purchase Agreement entered into on approximately the
same date of this Agreement (the 

 
“RSP Agreement”). Consultant shall be reimbursed for all reasonable and necessary expenses incurred by him while performing the Services,
subject to Consultant making best efforts to comply with the Company’s policy and procedures concerning reimbursement of such expenses in effect from time to time. 
 4. Covenant Not to Disclose. 
 (a) Consultant hereby covenants and agrees that, during the Term and
thereafter, he shall not communicate, disclose or otherwise make available to any person or entity (other than the Company), or use for his own account or for the benefit of any other person or entity, any information or materials proprietary to the
Company that relate to the Company’s business or affairs which is of a confidential nature, including, but not limited to, trade secrets, Inventions (as defined below), information or materials relating to existing or proposed pharmaceutical
products (in all and various stages of development), “know-how”, marketing techniques and materials, marketing and development plans, customer lists and other customer information (including, but not limited to, current prospects), price
lists, pricing policies, personnel information and financial information (collectively, “Proprietary Information”). Proprietary Information includes any and all such information and materials, whether or not obtained by Consultant
with the knowledge and permission of the Company, whether or not developed, devised or otherwise created in whole or in part by Consultant’s efforts, and whether or not a matter of public knowledge unless as a result of authorized disclosure.
Consultant further covenants and agrees that he shall retain such knowledge and information which he acquires and develops during the Term respecting such Proprietary Information in trust for the sole and exclusive benefit of the Company and its
successors and assigns. 
 (b) The provisions of this Section 4 shall apply to Proprietary Information obtained by the Company from any
third party under an agreement including, but not limited to, restrictions on disclosure. 
 5. Inventions. 
 (a) Consultant hereby covenants and agrees that he shall promptly disclose to the Company all ideas, inventions, discoveries and improvements (including,
but not limited to, those which are or may be patentable or subject to copyright protection (whether federal or at common law)) which he makes, originates, conceives or reduces to practice, either alone or jointly with 
 other(s), prior to or during the Term, and in connection with either (a) performance of the Services or other work performed by Consultant for the Company or
(b) result from use of equipment, materials or Proprietary Information (collectively, “Inventions”). All Inventions shall be deemed “works for hire” and shall be the sole and exclusive property of the Company, and
Consultant hereby assigns, and to the extent any such assignment cannot be made at present, hereby agrees to assign, to the Company all rights therein (including, but not limited to, patents, copyrights, trade secrets and other protections thereon
or with respect thereto (as the case may be) throughout the world) without further compensation, except as may otherwise be specifically agreed by the Company in writing. 
 (b) In order that the Company may protect its rights in the Inventions, Consultant hereby covenants and agrees that he shall make adequate written records of all Inventions, which records shall be the Company’s
property; and, both during and after the Term 

  

 2 

 
he shall, without charge to the Company but at its request and expense, sign all papers, including, but not limited to, forms of assignment, and render any
other proper assistance necessary or desirable to transfer or record the transfer to the Company of his entire right, title and interest in and to the Inventions, and for the Company to obtain, maintain and enforce patents, copyrights, trade secrets
or other protections thereon or with respect thereto (as the case may be) throughout the world. 
 (c) The obligations contained in this
Section 5 shall continue beyond the Term with respect to Inventions (whether patentable or copyrightable or not) conceived or made by Consultant during the Term. 
 (d) By this Agreement, Consultant irrevocably constitutes and appoints an officer of the Company as his attorney-in-fact for the purpose of executing, in his name and on his behalf, such instruments or other documents
as may be necessary to transfer, confirm and perfect in the Company the rights Consultant has granted to the Company in this Section 5. 
 6. Covenant Not to Compete; Non-Interference. 
 (a) Consultant hereby covenants and agrees that during the Term and for a
period of two (2) years thereafter he shall not, without the prior written consent of the Company, directly or indirectly, whether alone or in association with others, either as principal, agent, employee, consultant, representative or in any
other capacity, own, manage, operate or control, or be connected or employed by, render advisory consultations or other services to, or otherwise associate in any manner with, any business where the relationship therewith is specifically associated
with the field of agents that target any Microsomal Triglyceride Transport Protein as a clinically meaningful mechanism of action. 
 (b)
Consultant hereby covenants and agrees that he shall not, whether for his own account or for the account of any other person or entity, at any time during or after the Term, interfere with the relationship of the Company with or, at any time during
the Term and for a period of two (2) years following termination of this Agreement, contact or solicit the business of, or endeavor to entice away from the Company, any person or entity which at any time during the Term was an employee,
consultant, representative, client or customer of, or in the habit of dealing with, the Company. 
 7. Covenant to Report; Documents and
Tangible Property. Consultant hereby covenants and agrees that he shall promptly communicate and disclose to the Company all observations made and data obtained by him in the course of his relationship with the Company. All written materials,
records, documents and other tangible property made by Consultant or coming into his possession during the Term concerning the business or affairs of the Company, including, but not limited to, any Inventions, shall be the sole property of the
Company and, upon the termination of Consultant’s consulting relationship (or at such earlier time as the Company may request Consultant to do so), Consultant shall promptly deliver the same to the Company or to any party designated by it,
without retaining any copies, notes or excerpts thereof. Consultant hereby covenants and agrees to render to the Company, or to any party 
 designated by it,
such reports of the activities undertaken by Consultant or conducted under his direction during the Term as the Company may request. 
  

 3 

 8. Cooperation with the Company after Termination. Following expiration or termination of this
Agreement for any reason (with or without cause), Consultant shall fully cooperate with the Company in all matters relating to the winding up of Consultant’s Services and the orderly transfer of such matters to any person designated by the
Company and shall promptly return to the Company all of the property of the Company and any other materials or information related to the Company, including, but not limited to, all work product, whether finished or unfinished, prepared or produced
by Consultant for the benefit of the Company under this Agreement. 
 9. No Conflict. Consultant hereby represents and warrants to the
Company that (a) this Agreement constitutes Consultant’s legal and binding obligation, enforceable against him in accordance with its terms, (b) his execution and performance of this Agreement does not and shall not breach any other
agreement, arrangements, understanding, obligation of confidentiality or employment relationship to which he is a party or by which he is bound, and (c) during the Term, he shall not enter into any agreement, either written or oral, in conflict
with this Agreement or his obligations hereunder. 
 10. Independent Contractor. It is understood and agreed that this Agreement does
not create any relationship of employer-employee, association, partnership or joint venture between the parties, nor create any implied licenses, nor constitute either party as the agent or legal representative of the other for any purpose
whatsoever, and the relationship of Consultant to the Company for all purposes, including, but not limited to, federal and state tax purposes, shall be one of independent contractor. Neither party shall have any right or authority to create any
obligation or responsibility, express or implied, on behalf or in the name of the other, or to bind the other in any manner whatsoever. 
 11. Remedies. Consultant acknowledges that the Company may have no adequate remedy at law if Consultant violates any of the terms of this Agreement. In such event, the Company shall have the right, in addition to any other rights and
remedies it may have, to obtain, in any court of competent jurisdiction, injunctive relief to restrain any breach or threatened breach hereof or otherwise to specifically enforce any of the provisions of this Agreement. 
 12. Miscellaneous. 
 (a) Successors
and Assigns; Entire Agreement; No Assignment; Severability. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors or heirs, distributees and personal representatives. This Agreement, along with
the RSP Agreement, contains the entire agreement between the parties with respect to the subject matter hereof and supersedes other prior and contemporaneous arrangements or understandings with respect thereto, including that certain term sheet
between the parties dated January, 2006. Consultant may not assign this Agreement without the prior written consent of the Company. If any portion of this Agreement is deemed unenforceable, such provision shall be enforced to the fullest extent
permitted by law and the remainder of this Agreement shall remain in full force and effect. 
  

 4 

 (b) Notices. All notices, consents and other communications under this Agreement shall be in
writing and shall be deemed to have been duly given (a) when delivered by hand, (b) one (1) business day after the business day of transmission, if sent by telecopier (with receipt confirmed), provided that a copy is mailed by
registered mail, return receipt requested, or (c) one (1) business day after the business day of deposit with the carrier, if sent by Express Mail, Federal Express or other nationally-recognized express delivery service (receipt
requested), in each case to the appropriate addresses and telecopier numbers as follows: If to the Company: Aegerion Pharmaceuticals, c/o Scheer & Company, Inc., 250 West Main Street, Branford, CT 06405 Attention: President and Chief
Executive Office, Telecopier: (203) 4814164. If to Consultant: Antonio M. Gotto: c/o Aegerion Pharmaceuticals, Inc., 250 West Main Street, Branford, CT 06405. 
 (c) Changes; No Waiver. The terms and provisions of this Agreement may not be modified or amended, or any of the provisions hereof waived, temporarily or permanently, without the prior written consent of each
of the parties hereto. The Company’s waiver or failure to enforce the terms of this Agreement or any similar agreement in one instance shall not constitute a waiver of its rights hereunder with respect to other violations of this or any other
agreement. 
 (d) Governing Law; Jurisdiction. This Agreement and (unless otherwise provided) all amendments hereof and waivers and
consents hereunder shall be governed by the internal law of the State of New Jersey, without regard to the conflicts of law principles thereof. Each party hereby submits himself and itself, for the sole purpose of this Agreement and any controversy
arising hereunder, to the exclusive jurisdiction of the state and Federal courts located in the State of New Jersey, and waives any objection (on the grounds of lack of jurisdiction, forum non conveniens or otherwise) to the exercise of such
jurisdiction over it by any such court in the State of New Jersey. Each party hereby agrees that service of process may be served on him or it by certified mail, return receipt requested, or overnight courier, sent to address of such person or
entity listed in Section 12(b) (or such other address as any such party notifies the others thereof by written notice). 
 (e)
Survival. The obligations and responsibilities of Consultant under Sections 4, 5, 6, 7, 8, 10, 11 and 12 shall remain in full force and effect and survive expiration or termination of this Agreement. 
 (f) Fees and Expenses. Each party shall bear its own expenses for negotiating and entering into this Agreement and the RSP Agreement. Consultant
hereby agree that if the Company commences an action against Consultant, by way of claim or counterclaim and including, but not limited to, declaratory claims, in which it is preliminarily or finally determined that Consultant has violated any
provision of this Agreement, Consultant agrees to reimburse the Company for all cost and expenses incurred in such action, including but not limited to, the Company’s reasonable attorneys’ fees. 
 (g) Indemnification. The Company agrees to defend Consultant from any third party claims, suits or proceedings as a result of Consultant’s
provision of the Services to the Company (other than when acting in his role as a member of the Board, for which activities Consultant will be indemnified as required at law and by separate agreement with the Company), and the Company shall pay all
costs and damages finally awarded against Consultant by a court 

  

 5 

 
of competent jurisdiction or in accordance with any settlement of any such claim. Notwithstanding the foregoing, the Company shall not be obligated to defend
Consultant or be liable to Consultant to the extent that: (a) Consultant fails to comply with any applicable laws or regulations or policies of the Company or other entities or to adhere to the terms of the Board’s or SAB’s charter;
(b) Consultant breaches this Agreement, the RSP Agreement or any other agreement between the Company and Consultant; (c) the Company terminates Consultant for “Cause” (as defined in the RSP Agreement) or (d) the claim, suit,
proceeding, costs, and/or damages are the result of negligence or willful misconduct on the part of Consultant. Consultant shall give written notice to the Company immediately after receipt of notice of any claim or potential claim. Consultant shall
permit the Company to assume defense and/or control disposition of any such claim or related litigation in any manner that the Company deems appropriate, in its sole discretion. Consultant shall fully cooperate with the Company with respect to the
defense of the same. 
 (h) Headings; Counterparts and Facsimiles. The Section headings in this Agreement are inserted for
convenience, and shall not be considered in interpreting this Agreement. This Agreement may be executed in any number of counterparts, each such counterpart shall be deemed to be an original instrument, and all such counterparts together shall
constitute but one agreement. Facsimile transmission of execution copies or signature pages for this Agreement shall be legal, valid and binding execution and delivery for all purposes. 
 [Remainder of page is blank; signatures appear on next page.] 
  

 6 

 IN WITNESS WHEREOF, the parties have executed this Consulting Agreement as of the date first above
written. 
  

			
	 AEGERION PHARMACEUTICALS, INC.

		
	By:	 	 /s/ David Scheer

	Name:	 	David Scheer
	Title:	 	Chairman
	
	 CONSULTANT:

	
	 /s/ Antonio M. Gotto
 Antonio M. Gotto, Jr., M.D., D.Phil

  

 7 

 AMENDMENT TO TERMINATE 
 CONSULTING AGREEMENT 
 This Amendment to Terminate (this “Amendment”) is dated as of May
25, 2007, between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Antonio M. Gotto, Jr., M.D., D.Phil. (“Consultant”), and amends the Consulting Agreement between the Company and Consultant dated as of
April 4, 2006 (the “Agreement”). All capitalized terms used herein, but not defined, have the meaning given them in the Agreement. 
 1. Pursuant to Section 12(c) of the Agreement, the Company and Consultant hereby terminate the Agreement effective as of the closing of the Company’s initial firm commitment underwritten public offering of equity securities, provided
that the survival of certain obligations and responsibilities of Consultant, as set forth in Section 12(e) of the Agreement, shall survive the termination of the Agreement. 
 2. Reference is made to the Company’s Non-Employee Director Compensation Policy, which was approved by the Company’s Board of Directors on
April 24, 2007 in the form set forth as Exhibit A attached hereto, which policy will become effective as of the closing of the Company’s initial firm commitment underwritten public offering of equity securities. 
 3. This Amendment may be executed in any number of counterparts, and each such counterpart shall be deemed to be an original instrument and all such
counterparts together shall constitute but one agreement. Facsimile transmission of execution copies or signature pages for this Amendment shall be legal, valid and binding execution and delivery for all purposes. 
 In witness whereof, the parties have executed this Amendment as of the date first written above. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	/s/ Gerald Wisler
	Name:	 	Gerald Wisler
	Title:	 	President and Chief Executive Officer
	
	CONSULTANT
	
	/s/ Antonio M. Gotto
	Antonio M. Gotto, Jr. M.D., D.Phil.

 Exhibit A 
 AEGERION PHARMACEUTICALS, INC. 
 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 
 The purpose of this Director Compensation Policy of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is to provide a
total compensation package that enables the Corporation attract and retain, on a long-term basis, high caliber directors who are not employees or officers of the Corporation or its subsidiaries. This policy will become effective as of the closing of
the Company’s initial firm commitment underwritten public offering of equity securities (the “Effective Date”). 
 In
furtherance of this purpose, following the Effective Date, all non-employee directors shall be paid cash compensation for services provided to the Corporation as set forth below. 
  

										
	 	  	Annual Retainer	  	 In-Person
Attendance
 Per Meeting
	  	 Telephonic
Attendance
 Per Meeting

	 Board
	  			  			  		
	 Chairman of the Board
	  	$	35,000	  	$	1,000	  	$	500
	 Other Directors
	  	$	20,000	  	$	1,000	  	$	500
	 Audit Committee
	  			  			  		
	 Committee Chairman
	  	$	10,000	  	$	1,000	  	$	500
	 Committee Members
	  	$	7,500	  	$	1,000	  	$	500
	 Other Board Committees
	  			  			  		
	 Committee Chairman
	  	$	7,500	  	$	1,000	  	$	500
	 Committee Members
	  	$	5,000	  	$	1,000	  	$	500

 The Annual Retainer will be paid quarterly, in arrears, or upon the earlier resignation or removal of the
non-employee director. Amounts owing to non-employee directors as Annual Retainer shall be annualized, meaning that non-employee directors who join the board during the calendar year, and with respect to all non-employee directors for 2007, such
amounts shall be pro rated based on the number of calendar days served by such director. 
 The non-employee directors shall also be eligible
to participate in the Corporation’s stock option plans on a case by case basis. Following the Effective Date, each person who is appointed or elected to the Board of Directors, or is re-elected to the Board of Directors, as a non-employee
director will be eligible for an option grant to purchase 15,000 shares of common stock under the Corporation’s stock option plan on the date he or she first becomes a non-employee director (the “Director Option Grant”). For so long
as the director remains on the Board of Directors, the Director Option Grant shall vest one-third (1/3) on each one-year anniversary of the date of grant. Director Option Grants become immediately exercisable upon the death, disability or retirement
of a director or upon a change in control of the Company. In addition, the form of option agreement will give directors up to one year following cessation of service as a director to exercise the options (to the extent vested at the date of such
cessation), provided that the director has not been removed for cause. All of the foregoing options will be granted at fair market value on the date of grant. 
 The foregoing compensation will be in addition to reimbursement of all out-of-pocket expenses incurred by directors in attending meetings of the Board of Directors.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]